Today, Sanofi announced a series of changes that will make their insulins more affordable for people living with diabetes. This includes a reduction in the list price of Lantus (insulin glargine) and the establishment of a $35 monthly cap for individuals with commercial insurance. These changes are in addition to steps taken in June 2022 to lower costs for the uninsured.

JDRF is pleased that the three leading brand insulin manufacturers have taken steps recently to respond to the insulin affordability crisis in this country. Although the steps taken in the past few weeks are significant, there is still work to be done. We will continue to work with all stakeholders, including policy makers, and continue our support of Civica, a non-profit insulin manufacturer, to ensure insulin is accessible and affordable to all who depend on it, whether they have insurance or not.